 | |  |
Morphotek Names Mary Callan, Ph.D. Vice President, Business Development
Exton, PA - February 5, 2003 - Morphotek Inc. announced today the appointment of Mary Callan, Ph.D., to the position of Vice President of Business Development.
Prior to joining Morphotek, Dr. Callan was Director of Business Development at Exelixis, Inc., a leading genomics based drug discovery company. Preceding her tenure at Exelixis, Dr. Callan was head of Business Development at Large Scale Biology Corporation (LSBC), where she was a key member of the management team responsible for the company's successful $96 million public offering. During this time Dr. Callan was responsible for business development across all corporate functions, including pharmaceuticals, genomics, proteomics, and biomanufacturing. She was also responsible for corporate communications and investor relations during LSBC's public offering. Dr. Callan began her career in a research position at BASF Corporation in the U.S., enjoying positions of increased responsibility and eventually being promoted to a global position in business development at headquarters in Ludwigshafen, Germany.
"Morphotek is entering into a new phase of growth, focusing on the use of our platform technology for the rapid development biopharmaceutical products in the area of antibody and protein therapeutics as well as the development of high-titer manufacturing cell lines," said Nicholas C. Nicolaides, Ph.D., President and Chief Executive Officer of Morphotek. "I am delighted to have a person with Mary's experience in out-licensing and corporate development leading these business development efforts. She will be responsible for establishing strategic partnerships around our Human MORPHODOMA™ platform that generates fully human antibodies from high-titer human cell lines in addition to partnering lead therapeutic antibody products for the treatment of cancer."
Morphotek (www.morphotek.com) is a biotechnology company focused on the generation of proprietary organisms for product development using a patented platform technology that can enhance the natural process of genetic evolution within a targeted host. The technology has been successfully applied to microbes, plants, and mammals to yield genetically diverse offspring that are suitable for pharmaceutical and agricultural product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease.
For Information Contact:
Dr. Nicholas C. Nicolaides, President, CEO and CSO.
Morphotek Inc.
610-423-6100
| | |
